grant
Phenotypic consequences of lipoprotein(a) in diverse populations
Organization UNIV OF NORTH CAROLINA CHAPEL HILLLocation CHAPEL HILL, UNITED STATESPosted 15 Jan 2025Deadline 30 Nov 2028
NIHUS FederalResearch GrantFY2025AddressAdult-Onset Diabetes MellitusAdverse effectsAffectAfricanAfrican AmericanAfro AmericanAfroamericanAnemiaAnthropologyAsian groupAsian individualAsian peopleAsian populationAsiansAssayAtherogenicityBioassayBiological AssayBleedingBlood VesselsCardiac infarctionCausalityCerebral Brain HemorrhageCerebral HemorrhageCerebral Parenchymal HemorrhageCerebral hemisphere hemorrhageCerebrum HemorrhageClinicalCopy Number PolymorphismDataDecision MakingDiseaseDisorderEast AsianEpidemiologyEtiologyEuropeanEvaluationFoundationsFutureGWA studyGWASGene variantGeneticGenotypeHealthHeart failureHematologyHemorrhageHeritabilityHispanicIndigenousIndividualInflammatoryInfluentialsIntracerebral HemorrhageInvestigationKetosis-Resistant Diabetes MellitusKringle DomainsKringlesLatinoLipoprotein (a)Lipoprotein Lp(a)LipoproteinsLong-term cohortLongitudinal cohortLp(a)MapsMaturity-Onset Diabetes MellitusMeasurementMeasuresMedicineMendelian randomizationMetabolicMethodsModelingMyocardial InfarctMyocardial InfarctionNIDDMNational Institutes of HealthNon-Insulin Dependent DiabetesNon-Insulin-Dependent Diabetes MellitusNoninsulin Dependent DiabetesNoninsulin Dependent Diabetes MellitusParticipantPersonsPhenotypePolynesianPopulationPopulation GeneticsPopulation HeterogeneityPublic HealthPulmonary Body SystemPulmonary Organ SystemResearchRespiratory SystemRespiratory TractsRespiratory tract structureRisk FactorsRoleSlow-Onset Diabetes MellitusSouth AmericanSouth AsianStable Diabetes MellitusStatistical MethodsT2 DMT2DT2DMTherapeuticTherapeutic EffectTherapy Clinical TrialsType 2 Diabetes MellitusType 2 diabetesType II Diabetes MellitusType II diabetesUnited States National Institutes of Healthabdominal aortaadult onset diabetesallelic variantbiobankbiorepositoryblood losscardiac failurecardiac infarctcardiovascular disease riskcardiovascular disorder riskcausationcohortcopy number variantcopy number variationcoronary attackcoronary infarctcoronary infarctiondisease causationdiverse populationsepidemiologicepidemiologicalevidence basegenetic architecturegenetic variantgenome wide associationgenome wide association scangenome wide association studygenomewide association scangenomewide association studygenomic variantheart attackheart infarctheart infarctionheterogeneous populationinsightinterestketosis resistant diabetesmaturity onset diabetesnovelphenotypic datapolygenetic risk scorespolygenic risk scorepopulation diversityrisk minimizationsocial rolestatistic methodsthrombotictype 2 DMtype II DMtype two diabetesvascularvenous thromboembolismwhole genome association analysiswhole genome association study
Description preview
ABSTRACT
Lipoprotein(a) [Lp(a)], a highly atherogenic, prothrombotic, and proinflammatory lipoprotein, is a causal,
independent, and highly heritable {h2=70-90%) cardiovascular disease (CVD) risk factor that is elevated in 1.5
billion people globally. Despite significant stakes and emerging therapies that can reduce Lp(a) by >80%, few
overlooks…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click